دورية أكاديمية
Of lives and livers: emerging responses to the hepatitis C virus.
| العنوان: | Of lives and livers: emerging responses to the hepatitis C virus. |
|---|---|
| المؤلفون: | Noorali S; Department of Biology, Claflin University Orangeburg, SC, USA. shassanali@claflin.edu, Pace DG, Bagasra O |
| المصدر: | Journal of infection in developing countries [J Infect Dev Ctries] 2011 Feb 01; Vol. 5 (1), pp. 1-17. Date of Electronic Publication: 2011 Feb 01. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Open Learning on Enteric Pathogens Country of Publication: Italy NLM ID: 101305410 Publication Model: Electronic Cited Medium: Internet ISSN: 1972-2680 (Electronic) Linking ISSN: 19722680 NLM ISO Abbreviation: J Infect Dev Ctries Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: [Italy?] : Open Learning on Enteric Pathogens |
| مواضيع طبية MeSH: | Hepacivirus/*classification , Hepacivirus/*pathogenicity , Hepatitis C/*pathology , Hepatitis C/*virology , Liver/*pathology , Liver/*virology, Antiviral Agents/therapeutic use ; Drug Resistance, Viral ; Drug Therapy, Combination/methods ; Hepacivirus/genetics ; Hepatitis C/drug therapy ; Hepatitis C/transmission ; Humans ; Interferons/administration & dosage ; Ribavirin/administration & dosage ; Risk Factors ; Time Factors |
| مستخلص: | Hepatitis C is an infectious disease affecting the liver, caused by the hepatitis C virus (HCV). HCV is an etiological agent of acute and chronic liver disease that exists throughout the world. The high genetic variability of the HCV genome is reflected by six genotypes (1 to 6). Each genotype has a characteristic geographical distribution, which is important epidemiologically. HCV is a blood-borne virus that generally circulates in low titers in the serum of infected individuals. Epidemiologic studies show that the most efficient transmission of HCV is through the transfusion of blood or blood products, the transplantation of organs from infected donors, and the sharing of contaminated needles among injection-drug users. However, fewer than half of patients with acute hepatitis C report a history of such exposure. A small number of epidemiologic studies demonstrate that perinatal, sexual, household, and occupational transmission occurs, but our understanding of the risks of transmission in these settings has been limited. The therapy for chronic hepatitis C has evolved steadily since alpha interferon was first approved for use. At present, the optimal regimen appears to be a 24- or 48-week course of a combined pegylated alpha interferon and ribavirin regimen. Currently, the combination of RNAi (LV-shIRES) with IFN-α has been proposed to prevent therapeutic resistance, and to promote enhanced antiviral activity against HCV. However, any RNAi based therapy may be years away due to off-target effects. |
| المشرفين على المادة: | 0 (Antiviral Agents) 49717AWG6K (Ribavirin) 9008-11-1 (Interferons) |
| تواريخ الأحداث: | Date Created: 20110219 Date Completed: 20110531 Latest Revision: 20191112 |
| رمز التحديث: | 20221213 |
| DOI: | 10.3855/jidc.1169 |
| PMID: | 21330735 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1972-2680 |
|---|---|
| DOI: | 10.3855/jidc.1169 |